Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer

Francesco Picardo, Antonella Romanelli, Laura Muinelo-Romay, Tommaso Mazza, Caterina Fusilli, Paola Parrella, Jorge Barbazán, Rafael Lopez-López, Raffaela Barbano, Mariangela De Robertis, Chiara Taffon, Veronica Bordoni, Chiara Agrati, Manuela Costantini, Francesca Ricci, Paolo Graziano, Evaristo Maiello, Lucia Anna Muscarella, Vito Michele Fazio, Maria Luana Poeta

Research output: Contribution to journalArticle

Abstract

Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95% CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100% specificity and a 50% sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC.

Original languageEnglish
Article number1598
Pages (from-to)1-16
Number of pages16
JournalCancers
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 2019

Fingerprint

Colorectal Neoplasms
Biomarkers
DNA
Methylation
Neoplasm Metastasis
ROC Curve
Polymerase Chain Reaction
Kaplan-Meier Estimate
Drug Resistance
Epigenomics
Genes
Disease-Free Survival
Area Under Curve
Down-Regulation
Lung
Liver
Therapeutics
Neoplasms
Cetuximab

Keywords

  • B4GALT1
  • Cetuximab
  • CfDNA
  • Colorectal cancer
  • Liquid biopsy
  • Predictive biomarker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer. / Picardo, Francesco; Romanelli, Antonella; Muinelo-Romay, Laura; Mazza, Tommaso; Fusilli, Caterina; Parrella, Paola; Barbazán, Jorge; Lopez-López, Rafael; Barbano, Raffaela; De Robertis, Mariangela; Taffon, Chiara; Bordoni, Veronica; Agrati, Chiara; Costantini, Manuela; Ricci, Francesca; Graziano, Paolo; Maiello, Evaristo; Muscarella, Lucia Anna; Fazio, Vito Michele; Poeta, Maria Luana.

In: Cancers, Vol. 11, No. 10, 1598, 10.2019, p. 1-16.

Research output: Contribution to journalArticle

Picardo, Francesco ; Romanelli, Antonella ; Muinelo-Romay, Laura ; Mazza, Tommaso ; Fusilli, Caterina ; Parrella, Paola ; Barbazán, Jorge ; Lopez-López, Rafael ; Barbano, Raffaela ; De Robertis, Mariangela ; Taffon, Chiara ; Bordoni, Veronica ; Agrati, Chiara ; Costantini, Manuela ; Ricci, Francesca ; Graziano, Paolo ; Maiello, Evaristo ; Muscarella, Lucia Anna ; Fazio, Vito Michele ; Poeta, Maria Luana. / Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer. In: Cancers. 2019 ; Vol. 11, No. 10. pp. 1-16.
@article{a128808437e8476bbdb727b008f9c259,
title = "Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer",
abstract = "Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95{\%} CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100{\%} specificity and a 50{\%} sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC.",
keywords = "B4GALT1, Cetuximab, CfDNA, Colorectal cancer, Liquid biopsy, Predictive biomarker",
author = "Francesco Picardo and Antonella Romanelli and Laura Muinelo-Romay and Tommaso Mazza and Caterina Fusilli and Paola Parrella and Jorge Barbaz{\'a}n and Rafael Lopez-L{\'o}pez and Raffaela Barbano and {De Robertis}, Mariangela and Chiara Taffon and Veronica Bordoni and Chiara Agrati and Manuela Costantini and Francesca Ricci and Paolo Graziano and Evaristo Maiello and Muscarella, {Lucia Anna} and Fazio, {Vito Michele} and Poeta, {Maria Luana}",
year = "2019",
month = "10",
doi = "10.3390/cancers11101598",
language = "English",
volume = "11",
pages = "1--16",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer

AU - Picardo, Francesco

AU - Romanelli, Antonella

AU - Muinelo-Romay, Laura

AU - Mazza, Tommaso

AU - Fusilli, Caterina

AU - Parrella, Paola

AU - Barbazán, Jorge

AU - Lopez-López, Rafael

AU - Barbano, Raffaela

AU - De Robertis, Mariangela

AU - Taffon, Chiara

AU - Bordoni, Veronica

AU - Agrati, Chiara

AU - Costantini, Manuela

AU - Ricci, Francesca

AU - Graziano, Paolo

AU - Maiello, Evaristo

AU - Muscarella, Lucia Anna

AU - Fazio, Vito Michele

AU - Poeta, Maria Luana

PY - 2019/10

Y1 - 2019/10

N2 - Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95% CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100% specificity and a 50% sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC.

AB - Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95% CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100% specificity and a 50% sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC.

KW - B4GALT1

KW - Cetuximab

KW - CfDNA

KW - Colorectal cancer

KW - Liquid biopsy

KW - Predictive biomarker

UR - http://www.scopus.com/inward/record.url?scp=85074913270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074913270&partnerID=8YFLogxK

U2 - 10.3390/cancers11101598

DO - 10.3390/cancers11101598

M3 - Article

AN - SCOPUS:85074913270

VL - 11

SP - 1

EP - 16

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 1598

ER -